44 research outputs found

    Undiagnosed Phenylketonuria Can Exist Everywhere:Results From an International Survey

    Get PDF
    Many countries do not have a newborn screening (NBS) program, and immigrants from such countries are at risk for late diagnosis of phenylketonuria (PKU). In this international survey, 52 of 259 patients (20%) with late diagnosed PKU were immigrants, and 145 of the 259 (55%) were born before NBS or in a location without NBS

    Mapping of a new locus for congenital anomalies of the kidney and urinary tract on chromosome 8q24

    Get PDF
    Background. Congenital anomalies of the kidney and urinary tract (CAKUT) account for the majority of end-stage renal disease in children (50%). Previous studies have mapped autosomal dominant loci for CAKUT. We here report a genome-wide search for linkage in a large pedigree of Somalian descent containing eight affected individuals with a non-syndromic form of CAKUT. Methods. Clinical data and blood samples were obtained from a Somalian family with eight individuals with CAKUT including high-grade vesicoureteral reflux and unilateral renal agenesis. Total genome search for linkage was performed using a 50K SNP Affymetric DNA microarray. As neither parent is affected, the results of the SNP array were analysed under recessive models of inheritance, with and without the assumption of consanguinity. Results. Using the non-consanguineous recessive model, a new gene locus (CAKUT1) for CAKUT was mapped to chromosome 8q24 with a significant maximum parametric Logarithm of the ODDs (LOD) score (LODmax) of 4.2. Recombinations were observed in two patients defining a critical genetic interval of 2.5 Mb physical distance flanked by markers SNP_A-1740062 and SNP_A-1653225. Conclusion. We have thus identified a new non-syndromic recessive gene locus for CAKUT (CAKUT1) on chromosome 8q24. The identification of the disease-causing gene will provide further insights into the pathogenesis of urinary tract malformations and mechanisms of renal developmen

    Fluctuations in phenylalanine concentrations in phenylketonuria: a review of possible relationships with outcomes.

    Get PDF
    International audience; Fluctuations in blood phenylalanine concentrations may be an important determinant of intellectual outcome in patients with early and continuously treated phenylketonuria (PKU). This review evaluates the studies on phenylalanine fluctuations, factors affecting fluctuations, and if stabilizing phenylalanine concentrations affects outcomes, particularly neurocognitive outcome. Electronic literature searches of Embase and PubMed were performed for English-language publications, and the bibliographies of identified publications were also searched. In patients with PKU, phenylalanine concentrations are highest in the morning. Factors that can affect phenylalanine fluctuations include age, diet, timing and dosing of protein substitute and energy intake, dietary adherence, phenylalanine hydroxylase genotype, changes in dietary phenylalanine intake and protein metabolism, illness, and growth rate. Even distribution of phenylalanine-free protein substitute intake throughout 24h may reduce blood phenylalanine fluctuations. Patients responsive to and treated with 6R-tetrahydrobiopterin seem to have less fluctuation in their blood phenylalanine concentrations than controls. An increase in blood phenylalanine concentration may result in increased brain and cerebrospinal fluid phenylalanine concentrations within hours. Although some evidence suggests that stabilization of blood phenylalanine concentrations may have benefits in patients with PKU, more studies are needed to distinguish the effects of blood phenylalanine fluctuations from those of poor metabolic control

    Efficacy and outcome of expanded newborn screening for metabolic diseases - Report of 10 years from South-West Germany *

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>National newborn screening programmes based on tandem-mass spectrometry (MS/MS) and other newborn screening (NBS) technologies show a substantial variation in number and types of disorders included in the screening panel. Once established, these methods offer the opportunity to extend newborn screening panels without significant investment and cost. However, systematic evaluations of newborn screening programmes are rare, most often only describing parts of the whole process from taking blood samples to long-term evaluation of outcome.</p> <p>Methods</p> <p>In a prospective single screening centre observational study 373 cases with confirmed diagnosis of a metabolic disorder from a total cohort of 1,084,195 neonates screened in one newborn screening laboratory between January 1, 1999, and June 30, 2009 and subsequently treated and monitored in five specialised centres for inborn errors of metabolism were examined. Process times for taking screening samples, obtaining results, initiating diagnostic confirmation and starting treatment as well as the outcome variables metabolic decompensations, clinical status, and intellectual development at a mean age of 3.3 years were evaluated.</p> <p>Results</p> <p>Optimal outcome is achieved especially for the large subgroup of patients with medium-chain acyl-CoA dehydrogenase deficiency. Kaplan-Meier-analysis revealed disorder related patterns of decompensation. Urea cycle disorders, organic acid disorders, and amino acid disorders show an early high and continuous risk, medium-chain acyl-CoA dehydrogenase deficiency a continuous but much lower risk for decompensation, other fatty acid oxidation disorders an intermediate risk increasing towards the end of the first year. Clinical symptoms seem inevitable in a small subgroup of patients with very early disease onset. Later decompensation can not be completely prevented despite pre-symptomatic start of treatment. Metabolic decompensation does not necessarily result in impairment of intellectual development, but there is a definite association between the two.</p> <p>Conclusions</p> <p>Physical and cognitive outcome in patients with presymptomatic diagnosis of metabolic disorders included in the current German screening panel is equally good as in phenylketonuria, used as a gold standard for NBS. Extended NBS entails many different interrelated variables which need to be carefully evaluated and optimized. More reports from different parts of the world are needed to allow a comprehensive assessment of the likely benefits, harms and costs in different populations.</p

    The Genetic Landscape and Epidemiology of Phenylketonuria

    Get PDF
    Phenylketonuria (PKU), caused by variants in the phenylalanine hydroxylase (PAH) gene, is the most common autosomal-recessive Mendelian phenotype of amino acid metabolism. We estimated that globally 0.45 million individuals have PKU, with global prevalence 1:23,930 live births (range 1:4,500 [Italy]–1:125,000 [Japan]). Comparing genotypes and metabolic phenotypes from 16,092 affected subjects revealed differences in disease severity in 51 countries from 17 world regions, with the global phenotype distribution of 62% classic PKU, 22% mild PKU, and 16% mild hyperphenylalaninemia. A gradient in genotype and phenotype distribution exists across Europe, from classic PKU in the east to mild PKU in the southwest and mild hyperphenylalaninemia in the south. The c.1241A>G (p.Tyr414Cys)-associated genotype can be traced from Northern to Western Europe, from Sweden via Norway, to Denmark, to the Netherlands. The frequency of classic PKU increases from Europe (56%) via Middle East (71%) to Australia (80%). Of 758 PAH variants, c.1222C>T (p.Arg408Trp) (22.2%), c.1066−11G>A (IVS10−11G>A) (6.4%), and c.782G>A (p.Arg261Gln) (5.5%) were most common and responsible for two prevalent genotypes: p.[Arg408Trp];[Arg408Trp] (11.4%) and c.[1066−11G>A];[1066−11G>A] (2.6%). Most genotypes (73%) were compound heterozygous, 27% were homozygous, and 55% of 3,659 different genotypes occurred in only a single individual. PAH variants were scored using an allelic phenotype value and correlated with pre-treatment blood phenylalanine concentrations (n = 6,115) and tetrahydrobiopterin loading test results (n = 4,381), enabling prediction of both a genotype-based phenotype (88%) and tetrahydrobiopterin responsiveness (83%). This study shows that large genotype databases enable accurate phenotype prediction, allowing appropriate targeting of therapies to optimize clinical outcome.Fil: Hillert, Alicia. No especifĂ­ca;Fil: Anikster, Yair. No especifĂ­ca;Fil: Belanger Quintana, Amaya. No especifĂ­ca;Fil: Burlina, Alberto. No especifĂ­ca;Fil: Burton, Barbara K.. No especifĂ­ca;Fil: Carducci, Carla. No especifĂ­ca;Fil: Chiesa, Ana Elena. Consejo Nacional de Investigaciones CientĂ­ficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. Centro de Investigaciones EndocrinolĂłgicas "Dr. CĂ©sar Bergada". Gobierno de la Ciudad de Buenos Aires. Centro de Investigaciones EndocrinolĂłgicas "Dr. CĂ©sar Bergada". FundaciĂłn de EndocrinologĂ­a Infantil. Centro de Investigaciones EndocrinolĂłgicas "Dr. CĂ©sar Bergada"; ArgentinaFil: Christodoulou, John. No especifĂ­ca;Fil: Dordevic, Maja. No especifĂ­ca;Fil: Desviat, Lourdes R.. No especifĂ­ca;Fil: Eliyahu, Aviva. No especifĂ­ca;Fil: Evers, Roeland A.F.. No especifĂ­ca;Fil: Fajkusova, Lena. No especifĂ­ca;Fil: Feillet, Francois. No especifĂ­ca;Fil: Bonfim Freitas, Pedro E.. No especifĂ­ca;Fil: Gizewska, MarĂ­a. No especifĂ­ca;Fil: Gundorova, Polina. No especifĂ­ca;Fil: Karall, Daniela. No especifĂ­ca;Fil: Kneller, Katya. No especifĂ­ca;Fil: Kutsev, Sergey I.. No especifĂ­ca;Fil: Leuzzi, Vincenzo. No especifĂ­ca;Fil: Levy, Harvey L.. No especifĂ­ca;Fil: Lichter Koneck, Uta. No especifĂ­ca;Fil: Muntau, Ania C.. No especifĂ­ca;Fil: Namour, Fares. No especifĂ­ca;Fil: Oltarzewsk, Mariusz. No especifĂ­ca;Fil: Paras, Andrea. No especifĂ­ca;Fil: Perez, BelĂ©n. No especifĂ­ca;Fil: Polak, Emil. No especifĂ­ca;Fil: Polyakov, Alexander V.. No especifĂ­ca;Fil: Porta, Francesco. No especifĂ­ca;Fil: Rohrbach, Marianne. No especifĂ­ca;Fil: Scholl BĂŒrgi, Sabine. No especifĂ­ca;Fil: SpĂ©cola, Norma. No especifĂ­ca;Fil: Stojiljkovic, Maja. No especifĂ­ca;Fil: Shen, Nan. No especifĂ­ca;Fil: Santana da Silva, Luiz C.. No especifĂ­ca;Fil: Skouma, Anastasia. No especifĂ­ca;Fil: van Spronsen, Francjan. No especifĂ­ca;Fil: Stoppioni, Vera. No especifĂ­ca;Fil: Thöny, Beat. No especifĂ­ca;Fil: Trefz, Friedrich K.. No especifĂ­ca;Fil: Vockley, Jerry. No especifĂ­ca;Fil: Yu, Youngguo. No especifĂ­ca;Fil: Zschocke, Johannes. No especifĂ­ca;Fil: Hoffmann, Georg F.. No especifĂ­ca;Fil: Garbade, Sven F.. No especifĂ­ca;Fil: Blau, Nenad. No especifĂ­ca

    The Genetic Landscape and Epidemiology of Phenylketonuria

    Get PDF
    Phenylketonuria (PKU), caused by variants in the phenylalanine hydroxylase (PAH) gene, is the most common autosomal-recessive Mendelian phenotype of amino acid metabolism. We estimated that globally 0.45 million individuals have PKU, with global prevalence 1:23,930 live births (range 1:4,500 [Italy]-1:125,000 [Japan]). Comparing genotypes and metabolic phenotypes from 16,092 affected subjects revealed differences in disease severity in 51 countries from 17 world regions, with the global phenotype distribution of 62% classic PKU, 22% mild PKU, and 16% mild hyperphenylalaninemia. A gradient in genotype and phenotype distribution exists across Europe, from classic PKU in the east to mild PKU in the southwest and mild hyperphenylalaninemia in the south. The c.1241A gt G (p.Tyr414Cys)-associated genotype can be traced from Northern to Western Europe, from Sweden via Norway, to Denmark, to the Netherlands. The frequency of classic PKU increases from Europe (56%) via Middle East (71%) to Australia (80%). Of 758 PAH variants, c.1222C gt T (p.Arg408Trp) (22.2%), c.1066-11G gt A (IVS10-11G gt A) (6.4%), and c.782G gt A (p.Arg261Gln) (5.5%) were most common and responsible for two prevalent genotypes: p.[Arg408Trp];[Arg408Trp] (11.4%) and c.[1066-11G gt A];[1066-11G gt A] (2.6%). Most genotypes (73%) were compound heterozygous, 27% were homozygous, and 55% of 3,659 different genotypes occurred in only a single individual. PAH variants were scored using an allelic phenotype value and correlated with pre-treatment blood phenylalanine concentrations (n = 6,115) and tetrahydrobiopterin loading test results (n = 4,381), enabling prediction of both a genotype-based phenotype (88%) and tetrahydrobiopterin responsiveness (83%). This study shows that large genotype databases enable accurate phenotype prediction, allowing appropriate targeting of therapies to optimize clinical outcome

    Clinical presentation and outcome in a series of 88 patients with the cblC defect

    Get PDF
    The cblC defect is the most common inborn error of vitamin B12 metabolism. Despite therapeutic measures, the long-term outcome is often unsatisfactory. This retrospective multicentre study evaluates clinical, biochemical and genetic findings in 88 cblC patients. The questionnaire designed for the study evaluates clinical and biochemical features at both initial presentation and during follow up. Also the development of severity scores allows investigation of individual disease load, statistical evaluation of parameters between the different age of presentation groups, as well as a search for correlations between clinical endpoints and potential modifying factors. Results: No major differences were found between neonatal and early onset patients so that these groups were combined as an infantile-onset group representing 88% of all cases. Hypotonia, lethargy, feeding problems and developmental delay were predominant in this group, while late-onset patients frequently presented with psychiatric/behaviour problems and myelopathy. Plasma total homocysteine was higher and methionine lower in infantile-onset patients. Plasma methionine levels correlated with "overall impression” as judged by treating physicians. Physician's impression of patient's well-being correlated with assessed disease load. We confirmed the association between homozygosity for the c.271dupA mutation and infantile-onset but not between homozygosity for c.394C>T and late-onset. Patients were treated with parenteral hydroxocobalamin, betaine, folate/folinic acid and carnitine resulting in improvement of biochemical abnormalities, non-neurological signs and mortality. However the long-term neurological and ophthalmological outcome is not significantly influenced. In summary the survey points to the need for prospective studies in a large cohort using agreed treatment modalities and monitoring criteria

    RAMEDIS: a comprehensive information system for variations and corresponding phenotypes of rare metabolic diseases

    No full text
    Töpel T, Scheible D, Trefz F, HofestÀdt R. RAMEDIS: a comprehensive information system for variations and corresponding phenotypes of rare metabolic diseases. Human Mutation. 2010;31(1):E1081-E1088.RAMEDIS is a manually curated resource of human variations and corresponding phenotypes for rare metabolic diseases. The system is based on separate case reports that comprehensively describe various aspects of anonymous case study, e. g. molecular genetics, symptoms, lab findings, treatments, etc. Scientists are able to make use of the database by a simple and intuitive web-based user interface with a common web browser. A registration or login is not necessary for a full reading access to the system content. Furthermore, a mutation analysis table summarizes the submitted variations per diagnosis and enables direct access to detailed information of corresponding case reports. Interested scientists may open an account to submit their case reports in order to share valuable genotype-phenotype information efficiently with the scientific community. Currently, 794 case reports have been submitted, describing 92 different genetic metabolic diseases. To enhance the comprehensive coverage of available knowledge in the field of rare metabolic diseases, all case reports are linked to integrated information from public molecular biology databases like KEGG, OMIM and ENZYME. This information upgrades the case reports by related data of the corresponding diseases as well as involved enzymes, genes and metabolic pathways. Academic users may freely use the RAMEDIS system at http://www.ramedis.de. (C)2009 Wiley-Liss, Inc
    corecore